| Exposure groups* | Total | |
---|---|---|---|
 | Artemether-lumefantrine (N = 495) | Sulphadoxine-pyrimethamine (N = 506) | (N = 1001) |
Age - n (%) | |||
   <20 years | 79 (16.0) | 81 (16.0) | 160 (16.0) |
   20-24 years | 167 (33.7) | 151 (29.8) | 318 (31.8) |
   25-29 years | 144 (29.1) | 148 (29.2) | 292 (29.2) |
   30-39 years | 101 (20.4) | 119 (23.5) | 220 (22.0) |
   ≥ 40 years | 4 (0.8) | 7 (1.4) | 11 (1.1) |
Time of index malaria episode relative to LMP - n (%) | Â | Â | Â |
   Before LMP | 0 (0) | 2 (0.4) | 2 (0.2) |
   Date of LMP to 12 weeks | 145 (29.3) | 115 (22.7) | 260 (26.0) |
   >12 to 24 weeks | 169 (34.1) | 205 (40.5) | 374 (37.4) |
   >24 weeks | 162 (32.7) | 161 (31.8) | 323 (32.3) |
   LMP incomplete/unknown | 19 (3.8) | 23 (4.5) | 42 (4.2) |
Treatment courses during first trimester including IPT with SP - n (%) | Â | Â | Â |
   Only AL | 142 (28.7) | 5 (1.0) | 147 (14.7) |
   Only SP | 7 (1.4) | 120 (23.7) | 127 (12.7) |
   AL and SP | 8 (1.6) | 1 (0.2) | 9 (0.9) |
   SP plus quinine | 0 (0) | 2 (0.4) | 2 (0.2) |
   Only quinine | 2 (0.4) | 2 (0.4) | 4 (0.4) |
   None (including unknown LMP date) | 336 (67.9) | 376 (74.3) | 712 (71.1) |
Treatment received during current pregnancy **- n (%) | (N = 473) | (N = 478) | (N = 951) |
   Only AL or SP | 51 (10.8) | 449 (93.9) | 500 (52.6) |
   Both AL and SP | 412 (87.1) | 13 (2.7) | 425 (44.7) |
   AL or SP plus quinine | 1 (0.2) | 13 (2.7) | 14 (1.5) |
   Both AL and SP plus quinine | 9 (1.9) | 3 (0.6) | 12 (1.3) |
Alcohol status (current) | (N = 495) | (N = 506) | (N = 1001) |
   Non-drinker | 441 (89.1) | 437 (86.4) | 878 (87.7) |
   Drinker | 14 (2.8) | 17 (3.4) | 31 (3.1) |
   Unknown | 40 (8.1) | 52 (10.3) | 92 (9.2) |
Alcohol intake frequency | Â | Â | Â |
   Low | 11 (2.2) | 11 (2.2) | 22 (2.2) |
   Medium | 3 (0.6) | 5 (1.0) | 8 (0.8) |
   High | 0 | 1 (0.2) | 1 (0.1) |
Tobacco smoking history (current) | Â | Â | Â |
   Non-smoker | 455 (91.9) | 454 (89.7) | 909 (90.8) |
   Smoker | 0 | 0 | 0 |
   Unknown | 40 (8.1) | 52 (10.3) | 92 (9.2) |